Evidence map›Paper›PMID 42644279›Full record

ArticleEndocrinology2026

β-cell 14-3-3-ζ and sex are key regulators of α-cell form and function.

Rahaf Shishani, Rosalinda Moreno, Madelynn E Agabao-Tucker, Sofie E Dinglasan, Jessica Miranda Bustamante, Emily Eddy, Anna Jackson, Melanie A Reuter, Mara K Hon, Mark O Huising and 2 more

Abstract read
In one paragraph

Article in Endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rahaf ShishaniDivision of Foregut, Metabolic, and General Surgery, Department of Surgery, Center for Alimentary and Metabolic Sciences, School of Medicine, University of California-Davis, Sacramento, CA 95817, USA.
Rosalinda MorenoDivision of Foregut, Metabolic, and General Surgery, Department of Surgery, Center for Alimentary and Metabolic Sciences, School of Medicine, University of California-Davis, Sacramento, CA 95817, USA.
Madelynn E Agabao-TuckerDivision of Foregut, Metabolic, and General Surgery, Department of Surgery, Center for Alimentary and Metabolic Sciences, School of Medicine, University of California-Davis, Sacramento, CA 95817, USA.
Sofie E DinglasanDivision of Foregut, Metabolic, and General Surgery, Department of Surgery, Center for Alimentary and Metabolic Sciences, School of Medicine, University of California-Davis, Sacramento, CA 95817, USA.
Jessica Miranda BustamanteDivision of Foregut, Metabolic, and General Surgery, Department of Surgery, Center for Alimentary and Metabolic Sciences, School of Medicine, University of California-Davis, Sacramento, CA 95817, USA.
Emily EddyDivision of Foregut, Metabolic, and General Surgery, Department of Surgery, Center for Alimentary and Metabolic Sciences, School of Medicine, University of California-Davis, Sacramento, CA 95817, USA.
Anna JacksonDivision of Foregut, Metabolic, and General Surgery, Department of Surgery, Center for Alimentary and Metabolic Sciences, School of Medicine, University of California-Davis, Sacramento, CA 95817, USA.
Melanie A ReuterDivision of Foregut, Metabolic, and General Surgery, Department of Surgery, Center for Alimentary and Metabolic Sciences, School of Medicine, University of California-Davis, Sacramento, CA 95817, USA.
Mara K HonDivision of Foregut, Metabolic, and General Surgery, Department of Surgery, Center for Alimentary and Metabolic Sciences, School of Medicine, University of California-Davis, Sacramento, CA 95817, USA.
Mark O HuisingDepartment of Neurobiology, Physiology and Behavior, College of Biological Sciences, University of California-Davis, Davis, CA 95616, USA.
Gareth E LimDepartment of Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada.
Bethany P CummingsDivision of Foregut, Metabolic, and General Surgery, Department of Surgery, Center for Alimentary and Metabolic Sciences, School of Medicine, University of California-Davis, Sacramento, CA 95817, USA.ORCID 0000-0002-0610-9870

Funding

The Human Pancreas Analysis Program for Type 2 DiabetesU01DK123594 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Robert Babak Faryabi, KLAUS H KAESTNER · 2019 to 2026
$25.0M
Stanford Islet Research CoreP30DK116074 · NIDDK · STANFORD UNIVERSITY · PI Seung K Kim · 2017 to 2026
$19.5M
Penn integrated Human Pancreas procurement and Analysis ProgramUC4DK112217 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI BETTS, MICHAEL R, FELDMAN, MICHAEL D · 2016 to 2020
$17.8M
Supplement to Integrated Program for Human Pancreas Procurement and AnalysisUC4DK112232 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ATKINSON, MARK A., POWERS, ALVIN C · 2016 to 2020
$8.4M
ENVIRONMENTAL TOXICOLOGYT32ES007059 · NIEHS · UNIVERSITY OF CALIFORNIA DAVIS · PI Laura S Van Winkle · 1985 to 2026
$7.9M
Human Pancreas Analysis Program-T2DU01DK123716 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ATKINSON, MARK A., BOTTINO, RITA · 2019 to 2024
$6.6M
Training Program in PharmacologyT32GM144303 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Donald M Bers, JOHANNES W HELL · 2022 to 2026
$2.1M
Students Training in Advanced Research (STAR) ProgramT35OD010956 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DANIKA L BANNASCH · 2012 to 2026
$1.6M
14-3-3-zeta regulation of islet healthR01DK139200 · NIDDK · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CUMMINGS, BETHANY PAIGE · 2024 to 2025
$799k
Defining alpha-cell proglucagon processing for type 2 diabetes treatmentR56DK124853 · NIDDK · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CUMMINGS, BETHANY PAIGE · 2020 to 2020
$387k
A novel role for 14-3-3-ζ in regulating islet cell crosstalkF31DK139734 · NIDDK · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Rahaf Shishani · 2024 to 2026
$128k
Canada End Diabetes OG-3-24-5838-GLCIHR Project PJT-186121Hartwell FoundationNIDDK NIH HHS F31 DK139734NIDDK NIH HHS F31DK139734NIDDK NIH HHS P30 DK116074NIDDK NIH HHS R01 DK139200NIDDK NIH HHS R01DK139200NIDDK NIH HHS R56 DK124853NIDDK NIH HHS R56DK124853NIDDK NIH HHS U01 DK123594NIDDK NIH HHS U01 DK123716NIDDK NIH HHS UC4 DK112217NIDDK NIH HHS UC4 DK112232NIEHS NIH HHS T32 ES007059NIGMS NIH HHS T32 GM144303NIH HHS T32ES007059NIH HHS T32GM144303NIH HHS T35 OD010956NIH HHS T35OD010956NSERC Discovery RPGIN-2024-04279Stanford Diabetes Research Center P30DK116074UC Davis Science Translation and Innovative Research
6 · The paper itself

Abstract

α-cells exhibit heterogeneity in their hormone production, whereby distinct α-cell subpopulations can be induced to produce active glucagon-like peptide-1 (GLP-1). However, the mechanisms that govern α-cell GLP-1 production remain poorly defined and whether these differ between sex is unknown. We previously identified 14-3-3-ζ as an indirect negative regulator of α-cell GLP-1 production in vitro. Therefore, we tested the hypothesis that β-cell 14-3-3-ζ ablation exerts sex-dependent protection against metabolic disease through alteration of the α-cell endocrine profile. Male and female mice with targeted manipulation of GLP-1 production in α-cells and 14-3-3-ζ expression in β-cells were studied. Further, publicly available human pancreas data were analyzed to identify sex-dependent differences in islet cell populations. Loss of α-cell-derived GLP-1 impaired β-cell compensation in response to high-fat diet-induced metabolic stress, and β-cell 14-3-3-ζ ablation improved glucose tolerance during a mixed-meal tolerance test in male, but not female, mice. Conversely, overexpression of 14-3-3-ζ blunted the effect of a GLP-1 receptor agonist to promote insulin secretion in male, but not female, mice. Further, β-cell 14-3-3-ζ ablation increased α-cell abundance in male mice while enhancing α-cell GLP-1 production and secretion in both sexes. Finally, α-cell numbers were higher in females compared to males in both mouse and human islets, and α-cell GLP-1 production was higher in females compared to male mice. Together, these findings identify β-cell 14-3-3-ζ as an upstream constraint on α-cell GLP-1 production and reveal sex-dependent regulation of α-cell abundance, establishing β-cell 14-3-3-ζ and biological sex as key determinants of α-cell GLP-1 production.

Indexed as

Glucagon-Secreting CellsInsulin-Secreting CellsAnimalsDiet, High-FatFemaleGlucagon-Like Peptide 1HumansInsulinMaleMiceMice, Inbred C57BLSex CharacteristicsSex FactorsGlucagon-Like Peptide 1Insulin14-3-3-ζGLP-1α-cell

Identifiers

PMID42644279
PMCPMC13621187

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.